CASI Pharmaceuticals, Inc. · OTC:CASIF

CASI Pharmaceuticals — Investor Presentation (August 2021)

37 slides from CASI Pharmaceuticals's investor presentation, August 2021

  1. Slide 1: Corporate Presentation

    Corporate Presentation August 2021

  2. Slide 2: Disclaimer

    Disclaimer This presentation contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act with respect to the outlook for expectations for future financial or business performance, strategies, expectations and goals. Forward-looking statements are subject to

  3. Slide 3: Table of Contents

    Table of Contents • Highlights …………………………………………………………………….. Page 4 • EVOMELA® …………………………………………………………………… Page 6 • CNCT19 ………………………………………………………………………… Page 8 • BI-1206 ….…………………………………………………………………….. Page 13 • CB-5339 ..……………………………………………………………………… Page 21 • CID-103 ………………………………………………………………………… Page 28

  4. Slide 4: CASI - Highlights

    CASI - Highlights • EVOMELA® launched in China − Strong growth in sales, with 2020 full-year revenue of $15 million and projected >80% growth in 2021 • CNCT19: CD19 CAR-T Cell Therapy − Granted Breakthrough Therapy Designation and on track for 2021 year end China NDA submission • BI-1206: Checkpoint

  5. Slide 5: Clinical Assets

    Clinical Assets U.S. FDA-Approved Products In-Licensed for Greater China Region In-Licensed CTA Filing & Review Phase 2 Registration NDA Filing & Indication Trial Review EVOMELA Multiple Myeloma Licensed and Commercially Available in China China Developed Innovative Cell Therapy with Co-Commercializ

  6. Slide 6: EVOMELA®

    EVOMELA® casi

  7. Slide 7: EVOMELA® Launched in China

    EVOMELA® Launched in China • Launched in mid-August 2019 – $15 million revenue for 2020, with full- year 2021 revenue guidance of more than 80% growth over 2020 • Only form of injectable melphalan commercially available in China • Used in preparative regimen for autologous stem cell transplant (“ASC

  8. Slide 8: CNCT19

    CNCT19 CD19 CAR-T Therapy Partner: Juventas 8

  9. Slide 9: CNCT19 – Cell Therapy Targeting Clinically Validated CD19 With Significant China Opportunity

    CNCT19 – Cell Therapy Targeting Clinically Validated CD19 With Significant China Opportunity • Targets CD19, B-cell surface protein – validated target for B-cell derived hematological malignancies • There are currently two FDA approved CD19 CAR-Ts: Yescarta® and Kymriah®, with over $1 billion sales

  10. Slide 10: CNCT19 – Interim Phase 1 clinical trial data favorable safety profile R/R B-ALL

    CNCT19 – Interim Phase 1 clinical trial data demonstrates favorable safety profile in patients with R/R B-ALL Key Phase 1 Study Parameters: • 20 patients treated with CD19 CAR-T cells and included in study analysis • Median dose of infused CNCT19 cells was 1.82 × 10 6 /kg body weight Encouraging Ear

  11. Slide 11: CNCT19 + HDT/ASCT – Pilot study in R/R B-NHL

    CNCT19 + HDT/ASCT – Pilot study suggests favorable safety profile in patients with R/R B-NHL Key Pilot Study Parameters: • Median dose of infused CNCT19 cells was 2×𝟏𝟎𝟔 per kg body weight (range, 1.7-4×106 ) Encouraging Early Results : • CR rate at 3 months and 6 months was 70% and 62.5%…

  12. Slide 12: CNCT19 – Juventas Development Timeline

    CNCT19 – Juventas Development Timeline • B-NHL Phase 2 / registration trial currently enrolling in China • B-ALL Phase 2 / registration trial currently enrolling in China • Breakthrough Therapy Designation received in December 2020 from China CDE for B-ALL indication • China NDA submission targeted

  13. Slide 13: BI-1206 Checkpoint Inhibitor Targeting FcγRIIB

    BI-1206 Checkpoint Inhibitor Targeting FcγRIIB Partner: BioInvent 13

  14. Slide 14: BI-1206 – The First Checkpoint Inhibitor Directed Towards Monoclonal Antibody Receptor Interaction

    BI-1206 – The First Checkpoint Inhibitor Directed Towards Monoclonal Antibody Receptor Interaction • First-in-class in hematology – no direct competitors • Fully human monoclonal antibody (“mAb”) that targets FcγRIIB • Acts like a Checkpoint Inhibitor, blocking FcγRIIB interaction to unleash antibod

  15. Slide 15: FcγRIIB – Single Inhibitory Antibody Checkpoint To Unlock Anti-Cancer Immunity

    FcγRIIB – Single Inhibitory Antibody Checkpoint To Unlock Anti- Cancer Immunity In Both Liquid And Solid Tumors Antibody Checkpoints T-Cell Checkpoints Activates Innate Immune System Adaptive immune System Part of the immune system that kills tumor cells, but also Part of the immune system that elim

  16. Slide 16: BI-1206 in NHL – Encouraging Responses From Patients Completing Induction Cycle

    BI-1206 in NHL – Encouraging Responses From Patients Completing Induction Cycle Including Two Enduring CRs • To date, 15 patients enrolled in Part A Responses from 6 of 9 patients completing induction cycle • 9 patients have been evaluated for response, 2 still on treatment 11 10 TO BE VERIFIED − Tw

  17. Slide 17: BI-1206 in NHL - Favorable Safety Profile And Manageable IRRs

    BI-1206 in NHL - Favorable Safety Profile And Manageable IRRs DLTs were associated to Infusion-related reactions (IRR’s): • Two cases of thrombocytopenia: − Only lab values, no clinical signs or bleeding − All patients have recovered rapidly, and lab values return to normal within days • Two cases o

  18. Slide 18: Phase 1/2a Clinical Trial in Combination with Pembrolizumab

    Phase 1/2a Clinical Trial in Combination with Pembrolizumab • A multicenter, open label, Phase 1/2a study in adults with advanced solid tumors who have relapsed or are refractory to anti-PD-1 or anti-PD-L1 therapy – approximately 60 patients across sites in the U.S. and SWE • High unmet medical need

  19. Slide 19: BI-1206 Upcoming Key Milestones

    BI-1206 Upcoming Key Milestones • Select RP2D, and move to expansion phase (part B) of the study (same patient population) • Include China in global clinical development strategy: implement part B of the study • EoP1 meeting with FDA planned for Q4 2021 − Discuss RP2D and new Phase 2 study design (p

  20. Slide 20: CASI – BioInvent Partnership: Developing and Commercializing BI-1206 in China

    CASI – BioInvent Partnership: Developing and Commercializing BI-1206 in China • Leverages CASI’s expertise, clinical/medical teams and established relationships with hematology KOLs, hospitals, medical centers and pharmacies to accelerate development and commercialization of BI-1206 in China − CASI

  21. Slide 21: CB-5339 VCP/P97 Inhibitor

    CB-5339 VCP/P97 Inhibitor Partner: Cleave Therapeutics 21

  22. Slide 22: CB-5339 - Clinical Stage Asset Inhibiting Novel Target VCP/p97

    CB-5339 - Clinical Stage Asset Inhibiting Novel Target VCP/p97 Novel target - VCP/p97 Lead Product - CB-5339 • VCP is a AAA ATPase enzyme that • A 2nd generation small molecule inhibitor of VCP/p97 extracts and unfolds proteins, with biochemical potency of 9 nM essential for cancer cell survival • A

  23. Slide 23: VCP/p97 Inhibition Plays a Key Role Regulating Protein Degradation

    VCP/p97 Inhibition Plays a Key Role Regulating Protein Degradation and Drives Cytotoxic Buildup of Proteins in the Endoplasmic Reticulum Endoplasmic Reticulum Endoplasmic Reticulum (ER) Association Degradation (ERAD) Lumen Target for Bortezomib and • Critical to protein homeostasis Aberrant protein

  24. Slide 24: Unique Role for VCP/p97 in the DNA Damage Response With Exquisite AML Sensitivity

    Evolving Understanding - Unique Role for VCP/p97 in the DNA Damage Response (DDR) With Exquisite AML Sensitivity • DNA damaging agents, such as 7+3, are standard of care in AML – but patients develop resistance due to upregulation of DNA damage response proteins1 • VCP/p97 plays a key role in this r

  25. Slide 25: VCP/p97 is an Attractive Broad Oncology Target

    VCP/p97 is an Attractive Broad Oncology Target 10 • Cleave’s agent, CB-5339, has impressive efficacy across a broad Cytotoxic Activity Across Broad Panels of Cancer Cell Lines panel of cancer cell lines with IC50s CB-5339 EC50 (µM) 1 in the sub-100nM for the most sensitive lines 72 hrs 100 nM – 1 µM

  26. Slide 26: Cleave CB-5339 Phase 1 Study Focused on AML/MDS

    Cleave CB-5339 Phase 1 Study Focused on AML/MDS Open to R/R AML/MDS and Myeloid Malignancies Monotherapy Dose Expansion Combination R/R AML at RP2D R/R AML at RP2D Accelerated Titration 3 + 3 Escalation Monotherapy Dose Expansion Combination Int./Higher Risk MDS Int./Higher Risk MDS • CB-5339 dosed

  27. Slide 27: Scientific Rationale for CB-5339 in Acute Myeloid Leukemia

    Scientific Rationale for CB-5339 in Acute Myeloid Leukemia • VCP/p97 has an emerging role in chromatin associated degradation and the DNA damage response (DDR) that can be leveraged to drive genomic stress and cytotoxicity in cancer. VCP CAD / DDR DNA Damage Cellular Genotoxic Stress Inhibition Disr

  28. Slide 28: CID-103 Fully human IgG1 anti-CD38 mAb

    CID-103 Fully human IgG1 anti-CD38 mAB 28

  29. Slide 29: CID-103: Fully human IgG1 anti-CD38 monoclonal antibody

    CID-103: Fully human IgG1 anti-CD38 monoclonal antibody • Exclusive global rights • Phase 1 trial target initiated in Q1 2021 • Fully human IgG1 anti-CD38 mAb recognizing a unique epitope • No overt infusion related reactions observed • Encouraging preclinical efficacy & safety profile compared to o

  30. Slide 30: Rapid Growth of Anti-CD38 Market

    Rapid Growth of Anti-CD38 Market Blockbuster Darzalex® surpasses $3B in Annual Sales • Multiple Myeloma Market Opportunity: − USA: 32,270 new cases /year; − China: 20,100 new cases/year; − Worldwide: 140,000 new cases per/year • Daratumumab (J&J’s Darzalex®) approved in U.S. and EU for Multiple Myel

  31. Slide 31: CID-103 (TSK011010) – Potential Advantage over Competitor CD38 mAbs

    CID-103 (TSK011010) – Potential Advantage over Competitor CD38 mAbs CID-103 Daratumumab Isatuximab CID-103 Targets a Different CD38 Epitope CID-103 Demonstrates Higher ADCC Activity over Daratumumab and Isatuximab 31 *Sources: AACR; Cancer Res 2018;78(13 Suppl):Abstract nr 3812. TUSK Therapeutics In

  32. Slide 32: CID-103 Demonstrates Survival Advantage over Competitor CD38 mAbs

    CID-103 Demonstrates Survival Advantage over Competitor CD38 mAbs 32 *Sources: AACR; Cancer Res 2018;78(13 Suppl):Abstract nr 3812. TUSK Therapeutics Internal Reports

  33. Slide 33: CID-103 Demonstrates Decreased RBC Binding And Interference With Pre Transfusion Test Methods

    CID-103 Demonstrates Decreased RBC Binding And Decreased Interference With Pre Transfusion Test Methods Binding to three human RBC donor samples demonstrates that Daratumumab has consistently increased dose- dependent binding compared to CID-103 • Saturable concentration-dependent binding to three C

  34. Slide 34: No Overt Infusion Related Reactions Observed with CID-103 in Cynomolgus Monkeys

    No Overt Infusion Related Reactions Observed with CID-103 in Cynomolgus Monkeys • Non-GLP Non-Human Primate Dose Range Finding Study: − No immediate systemic reaction (cytokine-release like syndrome) observed (16 animals dosed 0.03 to 10 mg/kg) in the Dose-Range Study in Cynomolgus monkeys • GLP Non

  35. Slide 35: Global Senior Management Team

    Global Senior Management Team Wei-Wu He, PhD Larry Zhang, Chairman and CEO President Jim Goldschmidt, PhD, Alex Zukiwski, MD, SVP, Business Chief Medical Officer Development 35

  36. Slide 36: CASI China Management Team

    CASI China Management Team Thomas Zhang, Junping Chen, PhD Cissy Wang, China Commercial GM Medical Director (CASI COO (CASI China) (CASI China) China) Jonathan You, Michael Wu GM of R&D and Mfg. Regulatory Director Site (CASI WUXI) (CASI China) 36

  37. Slide 37: Thank You

    Thank You

CASI Pharmaceuticals — Investor Presentation (August 2021) on 6ix